Click to search for your profile
Click to search for condition or expert
Click to open main menu
Save Condition
Bookmark
Share
Share
Condition
Clinical Trials for
Merkel Cell Carcinoma
Overview
Find a Doctor
Latest Advances
Clinical Trials
Clinical Trials
Search for trials
Filter
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Drug, Biological
Participants:
142
Start Date:
March 31, 2021
A Phase 1b/2 Multiple-Dose Study to Evaluate the Safety and Efficacy of XmAb18087 ± Pembrolizumab in Subjects With Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer (DUET-1-02) Protocol
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Biological
Participants:
48
Start Date:
February 1, 2021
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
Search for trials
Clinical Trial
Status:
Not yet recruiting
Phase:
N/A
Intervention Type:
Other
Participants:
150
Start Date:
January 2021
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
Clinical Trial
Status:
Recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
50
Start Date:
November 2020
A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.
Clinical Trial
Status:
Recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Radiation, Drug
Participants:
65
Start Date:
October 8, 2020
A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma
Clinical Trial
Status:
Recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
132
Start Date:
October 8, 2020
A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma
Clinical Trial
Status:
Recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Drug
Participants:
80
Start Date:
October 6, 2020
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
Clinical Trial
Status:
Recruiting
Phase:
Phase 1
Intervention Type:
Drug
Participants:
27
Start Date:
September 7, 2020
A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Clinical Trial
Status:
Recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
40
Start Date:
September 1, 2020
A Phase II, Open Label Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Advanced Unresectable/Metastatic Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 Antibody Therapy
Clinical Trial
Status:
Recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Biological
Participants:
45
Start Date:
August 10, 2020
Phase 1/2 Expansion Cohorts Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2- and PD-1/PD-L1 Antibodies in Patients With Advanced HER2-expressing Cancer
Clinical Trial
Status:
Recruiting
Phase:
Phase 1
Intervention Type:
Biological
Participants:
20
Start Date:
March 3, 2020
Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma
Clinical Trial
Status:
Recruiting
Phase:
Phase 2
Intervention Type:
Biological
Participants:
43
Start Date:
February 24, 2020
QUILT-3.063: A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects With Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment With a Checkpoint Inhibitor.
Showing 1-12 of 51
Next